Genomic Health, Inc. announced that the National Institute for Health and Care Excellence in the United Kingdom has issued its updated guidance again recommending the Oncotype DX Breast Recurrence Score test for use in clinical practice to guide adjuvant chemotherapy treatment decisions for certain patients with early-stage breast cancer. Further, NICE expanded its recommendation to include patients with micrometastases, indicating that some cancer cells have spread to the lymph nodes. The recommendation of the Oncotype DX Breast Recurrence Score test in NICE's updated guidance is based on the test's unique ability to predict who will benefit from chemotherapy and who will not. Importantly, NICE acknowledges Oncotype DX as the only test that reduces the overall number of patients who receive chemotherapy, as well as the only test supported by long-term patient outcomes evidence, including the recently published landmark TAILORx study. Further, NICE also found the Oncotype DX test to be the most cost effective tool in guiding chemotherapy treatment. The predictive value of the Oncotype DX Breast Recurrence Score test was also recently acknowledged by Germany's health technology assessment body, the Institute for Quality and Efficiency in Health Care (IQWiG), which concluded that only the Oncotype DX test has sufficient evidence to guide breast cancer adjuvant chemotherapy decisions based on the TAILORx study results. Additionally, the U.S. National Comprehensive Cancer Network (NCCN) categorized Oncotype DX as the only "preferred" test for chemotherapy treatment decision-making for node negative, early-stage breast cancer patients in its 2018 updated treatment guidelines.